Jefferson Life Sciences

Activity in this selectionjohnson-johnson-innovation-jjdc-403378e7

By stage

Series B2

Series A1

Biotech2

Healthtech1

United States2

United Kingdom1

3 in this selection

Jul 14

Developing transformative, best-in-class neuropsychiatric therapies

$65MSeries B

Role not disclosed

Jun 10

Develops FDA-cleared hydrogel dermal regeneration templates for wound healing and reconstructive surgery

$20MSeries A

Role not disclosed

Jan 12

Develops regenerative biologics to restore tissue function

$33.5MSeries B

Role not disclosed